Immunic, Inc. to Host Virtual R&D Day Today

Inc. to Host Virtual R&D Day Today, May 19, 2020

Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing

Phase 1 Clinical Trial of IMU-935 -

Live Webcast to be Held From 9:00 am to 1:00 pm ET -

YORK, May 19, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused

on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it

will host a virtual R&D Day today, May 19, 2020, from 9:00 am to 1:00 pm ET. Immunic's management and invited key opinion

leaders, specializing in multiple sclerosis and inflammatory bowel disease, will discuss today's treatment options for, and

the unmet medical needs of, chronic inflammatory and autoimmune diseases, as well as clinical progress of Immunic's selective

oral immunology programs and their potential advantages over the current treatment landscape. Management will also discuss the

company's coronavirus disease 2019 (COVID-19) program.

During the event, Immunic will provide

recently obtained preclinical data testing the company's lead asset, IMU-838, a selective oral DHODH inhibitor, against severe

acute respiratory syndrome coronavirus 2 (SARS-CoV-2), showing that, in in vitro models, IMU-838 is able to inhibit replication

of clinical isolates of SARS-CoV-2, obtained from patients with COVID-19, at drug concentrations consistent with previously employed

IMU-838 dosing regimens. Highlights will include:

Immunic will also present preclinical mode

of action and first pharmacokinetic data from the current, single ascending dose part in healthy volunteers of the ongoing phase

1 trial of IMU-935, a potentially best-in-class ROR t inverse agonist. Highlights will include:

full data sets will be publicly disclosed in a Current Report on Form 8-K.

from Immunic will be:

key opinion leaders will be:

(Eastern time, times are estimates):

in the live webcast, please follow this link:

webcast will be held in English. Questions can be asked via the question and answer tool any time during the presentation. An archived

replay of the webcast will be available on Immunic's website at: ir.imux.com.

Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies

aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis,

Crohn's disease, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator

that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist

of ROR t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program,

IMU-838, is in phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional

phase 2 trial considered in Crohn's disease. The company is also investigating IMU-838 as a potential treatment option for

COVID-19. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at

the Mayo Clinic. For further information, please visit: www.imux.com.

Statement Regarding Forward-Looking Statements

This press release contains "forward-looking

statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities

Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding

strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of

management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to

management's participation in conferences; Immunic's three development programs and the targeted diseases; the potential

for IMU-838 to safely and effectively target diseases; preclinical and clinical data for IMU-838; the timing of current and future

clinical trials; the potential for IMU-838 as a treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections

associated with coronavirus disease 2019 (COVID-19) and any clinical trials, collaborations and approvals relating to such potential

treatment; the nature, strategy and focus of the company; and the development and commercial potential of any product candidates

of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed

in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements

are based on management's current expectations and involve risks and uncertainties. Actual results and performance could

differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation,

the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed

for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives

and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical

trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug

development and the regulatory approval process and the impact of competitive products and technological changes. A further list

and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors,"

in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16,

2020, the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 8, 2020,

and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available

online at www.sec.gov or ir.immunic-therapeutics.com/sec-filings and on request from Immunic. Any forward-looking statement made

in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking

statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all

liability in respect to actions taken or not taken based on any or all the contents of this press release.

Manager Investor Relations and Communications

Rx Communications Group

Knight Marketing Communications, Ltd.